Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
11 pending office actions • 6 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 22 patents granted in the last 365 days
Pusan National University Industry-university Cooperation Foundation is managing 9 pending office actions in the Chemistry & Materials technology area. These 9 actions are distributed among 9 distinct examiners, meaning each pending matter is being handled by a different individual. TORIANA NICHOLE VIGIL is the busiest examiner for the portfolio, currently responsible for 1 pending office action. This high number of examiners relative to the total actions suggests a very fragmented prosecution landscape.
The 9 pending actions are spread across 4 distinct art units, which indicates that the university's chemistry and materials research spans several different technical classifications. Because each of the 9 examiners holds only 1 pending action, the university must manage 9 separate examiner relationships simultaneously. This profile reflects a diverse filing strategy where the workload is not clustered, requiring a broad approach to navigate the 4 different art units involved.
Practitioners should be prepared for 9 unique negotiation styles, as the lack of examiner overlap prevents the use of common strategies across multiple cases. The 4 distinct art units further diversify the technical requirements for the 9 pending office actions. Managing this portfolio effectively requires a high degree of coordination to address the specific tendencies of 9 different examiners across 4 specialized technical groups.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (45%) |
| Double-patenting + other | 1 (9%) |
| Multi-statute (no §101) | 5 (45%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIGIL, TORIANA NICHOLE | 1 | 53.1% | +24.1% |
| SHAIKH, MERAJ A | 1 | 57.3% | +22.3% |
| BERRESFORD, JORDAN ELIZABETH | 1 | 68.1% | +6.1% |
| SPENCE, JENNIFER SUZANNE | 1 | 66.9% | +46.0% |
| HOWELL, THEODORE R | 1 | 66.8% | +25.3% |
| KARST, DAVID THOMAS | 1 | 64.7% | +9.8% |
| KWAK, DEAN P | 1 | 58.7% | +37.1% |
| BUTCHER, ROBERT T | 1 | 71.1% | +17.0% |
| WELLS, LAUREN QUINLAN | 1 | 48.4% | +60.3% |
| BENNETT, CHARLEE | 1 | 58.6% | +34.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18144230 | PHARMACEUTICAL COMPOSITION FOR COMBINATION THERAPY COMPRISING MELATONIN AND PROSTAGLANDIN E2 FOR TREATING INTESTINAL EPITHELIAL INJURY AS AN ACTIVE INGREDIENT | WELLS, LAUREN QUINLAN | 2d overdue |
| 19020111 | 3D PRINTED ARTIFICIAL BILE DUCTS AND MANUFACTURING METHOD THEREOF | VIGIL, TORIANA NICHOLE | — |
| 18657888 | ELECTROLYTE FOR LITHIUM SECONDARY BATTERIES AND LITHIUM SECONDARY BATTERIES CONTAINING THE SAME | BERRESFORD, JORDAN ELIZABETH | — |
| 18699698 | PHARMACEUTICAL COMPOSITION CONTAINING 27-HYDROXYCHOLESTEROL FOR PREVENTING OR TREATING MYELOID LEUKEMIA | HOWELL, THEODORE R | — |
| 18392383 | A Biomarker for Breast Cancer Diagnosis Using Estrogen in Exosomes and a Breast Cancer Diagnosis Kit Using the Biomarker | KWAK, DEAN P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18144230 | PHARMACEUTICAL COMPOSITION FOR COMBINATION THERAPY COMPRISING MELATONIN AND PROSTAGLANDIN E2 FOR TREATING INTESTINAL EPITHELIAL INJURY AS AN ACTIVE INGREDIENT | WELLS, LAUREN QUINLAN | 2d overdue |
| 19020111 | 3D PRINTED ARTIFICIAL BILE DUCTS AND MANUFACTURING METHOD THEREOF | VIGIL, TORIANA NICHOLE | — |
| 18929035 | REFRIGERATOR USING A WATER-COOLED CONDENSER | SHAIKH, MERAJ A | — |
| 18654005 | UT2 GENE-DEFICIENT MOUSE MODEL AND METHOD FOR SCREENING THERAPEUTIC AGENT FOR MYELOID LEUKEMIA, USING SAME | SPENCE, JENNIFER SUZANNE | — |
| 18699698 | PHARMACEUTICAL COMPOSITION CONTAINING 27-HYDROXYCHOLESTEROL FOR PREVENTING OR TREATING MYELOID LEUKEMIA | HOWELL, THEODORE R | — |
| 18392383 | A Biomarker for Breast Cancer Diagnosis Using Estrogen in Exosomes and a Breast Cancer Diagnosis Kit Using the Biomarker | KWAK, DEAN P | — |
| 18369487 | RECYCLABLE VITRIMER POLYMER, LIGHTWEIGHT HEAT-DISSIPATING POLYMER COMPOSITE COMPRISING THE SAME, AND MANUFACTURING METHOD THEREOF | BUTCHER, ROBERT T | — |
| 18055917 | APPARATUS FOR TREATING SUBSTRATE | BENNETT, CHARLEE | — |
| Art Unit | Apps |
|---|---|
| 3763 | 1 |
| 1628 | 1 |
| 1764 | 1 |
| 1622 | 1 |
| 1718 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19020111 | 3D PRINTED ARTIFICIAL BILE DUCTS AND MANUFACTURING METHOD THEREOF | VIGIL, TORIANA NICHOLE | — | §103§112 | Non-Final OA | — | Pending | Jan 14, 2025 |
| 18929035 | REFRIGERATOR USING A WATER-COOLED CONDENSER | SHAIKH, MERAJ A | 3763 | §103Other | Final Rejection | — | Pending | Oct 28, 2024 |
| 18657888 | ELECTROLYTE FOR LITHIUM SECONDARY BATTERIES AND LITHIUM SECONDARY BATTERIES CONTAINING THE SAME | BERRESFORD, JORDAN ELIZABETH | — | §102§103 | Non-Final OA | — | Pending | May 08, 2024 |
| 18654005 | UT2 GENE-DEFICIENT MOUSE MODEL AND METHOD FOR SCREENING THERAPEUTIC AGENT FOR MYELOID LEUKEMIA, USING SAME | SPENCE, JENNIFER SUZANNE | — | §103 | Non-Final OA | — | Pending | May 03, 2024 |
| 18699698 | PHARMACEUTICAL COMPOSITION CONTAINING 27-HYDROXYCHOLESTEROL FOR PREVENTING OR TREATING MYELOID LEUKEMIA | HOWELL, THEODORE R | 1628 | §102§112 | Final Rejection | — | Pending | Apr 09, 2024 |
| 18413582 | Novel diamine compound, reactive monomer for polyimide precursor containing the same, and polyimide film prepared therefrom | KARST, DAVID THOMAS | — | §103 | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18392383 | A Biomarker for Breast Cancer Diagnosis Using Estrogen in Exosomes and a Breast Cancer Diagnosis Kit Using the Biomarker | KWAK, DEAN P | — | §102§112Other | Non-Final OA | — | Pending | Dec 21, 2023 |
| 18369487 | RECYCLABLE VITRIMER POLYMER, LIGHTWEIGHT HEAT-DISSIPATING POLYMER COMPOSITE COMPRISING THE SAME, AND MANUFACTURING METHOD THEREOF | BUTCHER, ROBERT T | 1764 | §103 | Final Rejection | — | Pending | Sep 18, 2023 |
| 18144230 | PHARMACEUTICAL COMPOSITION FOR COMBINATION THERAPY COMPRISING MELATONIN AND PROSTAGLANDIN E2 FOR TREATING INTESTINAL EPITHELIAL INJURY AS AN ACTIVE INGREDIENT | WELLS, LAUREN QUINLAN | 1622 | §103§112 | Non-Final OA | 2d overdue | Pending | May 07, 2023 |
| 18055917 | APPARATUS FOR TREATING SUBSTRATE | BENNETT, CHARLEE | 1718 | §103§112DP | Non-Final OA | — | Pending | Nov 16, 2022 |
| 16633701 | COMPOUND AND METHOD FOR PRODUCING THE SAME | LEE, JIA-HAI | 1658 | §103 | Final Rejection | — | Pending | Jan 24, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial